Physician profile
Lynn Gamble
NPI 1770742884
$9,716.70
in general payments reported to CMS, 2019-2025
25 companies · $3,715 in 2025
The $3,715 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $1,084 · 2023: $2,162 · 2024: $2,418 · 2025: $3,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,254 · Education: $40.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,254.05 |
| Education | $40.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,685.92 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,573.74 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $767.09 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Bausch Health US, LLC | $741.72 | 2021-2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $586.54 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $566.03 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $528.26 | 2021-2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $501.64 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $442.63 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $402.81 | 2023-2025 | |
| Almatica Pharma LLC | $388.99 | 2022-2025 | Loreev Xr |
| Corium, LLC | $306.24 | 2022-2024 | Azstarys |
| Alkermes, INC. | $291.39 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $174.68 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $135.89 | 2023-2024 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $101.90 | 2023-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $88.94 | 2021-2023 | Belsomra |
| Boston Scientific Corporation | $85.71 | 2023 | Varithena Administration Pack |
| Collegium Pharmaceutical, INC. | $72.12 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $70.95 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $70.08 | 2023-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $43.15 | 2024-2025 | Trintellix |
| Indivior INC. | $42.20 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $30.41 | 2022 | |
| Braeburn INC. | $17.67 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.